© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 161 Farringdon Rd, London EC1R 3AL. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

High grade and crossover bonds

Top Section/Ad

Top Section/Ad

Most recent


Proceeds earmarked to refinance upcoming maturity
◆ Strong demand for first sterling bond under Andy Burnham's government ◆ Deal navigates market vol ◆ Concession small, but investors attracted to spread
◆ French real estate group prints seven year bond ◆ Covivio skips guidance and tightens spread sharply ◆ Investor selectivity returns as orders fall
Bifurcation is emerging in how investors treat the hyperscalers
More articles/Ad

More articles/Ad

More articles

  • China Minmetals Corp printed its first dollar bond of the year on Wednesday, replicating the same structure as its last outing a year ago. While some market participants reckoned the issuer was aggressive with pricing, the secondary performance of the notes indicated otherwise.
  • Greenland Hong Kong and China Railway Group opened books for their respective dollar bonds on Thursday after meetings with investors earlier this week.
  • Israeli-American pharmaceutical company Teva made a swift entry into the European investment grade corporate bond market on Wednesday, winning an order book to rival AB-InBev’s €13.25bn record breaker.
  • China Minmetals Corp started attracting attention from investors on Wednesday morning, taking bids for a dollar offering divided into a five and 10 year.
  • ONGC Videsh made an opportunistic move on Tuesday, taking advantage of abundant market liquidity to achieve what some considered an aggressively priced bond. But with expectations high that the window for issuance is short lived, more credits from the high beta country will keep knocking on investors’ doors.
  • With its $15bn of new bonds ratcheting tighter, Israeli-American pharmaceutical company Teva has set out the structure of the euro part of its M&A bond financing for the acquisition of Allergan's generic drugs business.